Limits...
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos TD - Cardiovasc Drugs Ther (2012)

Bottom Line: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies.The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece. filtheo@gmail.com

ABSTRACT
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

Show MeSH

Related in: MedlinePlus

Design of the pivotal trials evaluating the efficacy and safety of the combined use of fenofibric acid (FA) with different statins in patients with mixed dyslipidemia
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3368211&req=5

Fig1: Design of the pivotal trials evaluating the efficacy and safety of the combined use of fenofibric acid (FA) with different statins in patients with mixed dyslipidemia

Mentions: The efficacy and safety of FA has been evaluated in a large well-designed phase III clinical program consisting of three separate double-blind, randomized, active control trials (Fig. 1) [21]. In each trial patients were randomized in a ratio of 2:2:2:2:2:1 to one of six arms:


A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos TD - Cardiovasc Drugs Ther (2012)

Design of the pivotal trials evaluating the efficacy and safety of the combined use of fenofibric acid (FA) with different statins in patients with mixed dyslipidemia
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3368211&req=5

Fig1: Design of the pivotal trials evaluating the efficacy and safety of the combined use of fenofibric acid (FA) with different statins in patients with mixed dyslipidemia
Mentions: The efficacy and safety of FA has been evaluated in a large well-designed phase III clinical program consisting of three separate double-blind, randomized, active control trials (Fig. 1) [21]. In each trial patients were randomized in a ratio of 2:2:2:2:2:1 to one of six arms:

Bottom Line: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies.The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece. filtheo@gmail.com

ABSTRACT
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

Show MeSH
Related in: MedlinePlus